MIT News profiled Michael Birnbaum’s efforts to develop large scale screening tools to decipher how diverse T cells recognize their targets. Birnbaum co-founded Kelonia, which is adapting the approach to reprogram T cells to target specific antigens directly inside the body to treat a broad range of diseases including cancer, autoimmune disorders, and viral infections.